$BOLT
Bolt Biotherapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021044002 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $0.00 $67.00K $164.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.054M $4.133M $2.120M
YoY Change -1.91%
% of Gross Profit
Research & Development $19.71M $9.166M $6.787M
YoY Change 115.0%
% of Gross Profit
Depreciation & Amortization $200.0K $100.0K $101.0K
YoY Change 100.0% -33.33%
% of Gross Profit
Operating Expenses $23.76M $11.18M $8.909M
YoY Change 112.59%
Operating Profit -$23.76M -$11.11M -$8.745M
YoY Change 113.87%
Interest Expense $176.0K $163.0K $110.0K
YoY Change 7.98%
% of Operating Profit
Other Income/Expense, Net $176.0K $51.00K $112.0K
YoY Change 245.1%
Pretax Income -$23.59M -$19.69M -$8.630M
YoY Change 19.77%
Income Tax
% Of Pretax Income
Net Earnings -$23.59M -$11.06M -$8.633M
YoY Change 113.27%
Net Earnings / Revenue -16505.97% -5264.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$644.5K -$570.4K -$0.25
COMMON SHARES
Basic Shares Outstanding 36.62M 1.938M 1.934M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $245.0M $53.30M
YoY Change 359.64%
Cash & Equivalents $58.30M $45.31M $11.61M
Short-Term Investments $186.7M $8.000M
Other Short-Term Assets $3.163M $1.300M
YoY Change 143.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $248.2M $54.60M
YoY Change 354.49%
LONG-TERM ASSETS
Property, Plant & Equipment $4.551M $12.30M
YoY Change -63.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $65.94M
YoY Change
Other Assets $2.432M $1.200M
YoY Change 102.67%
Total Long-Term Assets $98.92M $13.50M
YoY Change 632.76%
TOTAL ASSETS
Total Short-Term Assets $248.2M $54.60M
Total Long-Term Assets $98.92M $13.50M
Total Assets $347.1M $68.10M
YoY Change 409.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.614M $1.800M
YoY Change -10.33%
Accrued Expenses $13.31M $4.500M
YoY Change 195.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change
Total Short-Term Liabilities $19.25M $7.900M
YoY Change 143.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $31.93M $19.90M
YoY Change 60.44%
Total Long-Term Liabilities $31.93M $19.90M
YoY Change 60.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.25M $7.900M
Total Long-Term Liabilities $31.93M $19.90M
Total Liabilities $51.18M $27.80M
YoY Change 84.09%
SHAREHOLDERS EQUITY
Retained Earnings -$156.4M
YoY Change
Common Stock $452.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $295.9M -$65.04M -$54.23M
YoY Change
Total Liabilities & Shareholders Equity $347.1M $68.10M
YoY Change 409.65%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$23.59M -$11.06M -$8.633M
YoY Change 113.27%
Depreciation, Depletion And Amortization $200.0K $100.0K $101.0K
YoY Change 100.0% -33.33%
Cash From Operating Activities -$3.985M -$21.90M -$9.638M
YoY Change -81.8% 85.59%
INVESTING ACTIVITIES
Capital Expenditures -$701.0K -$1.210M $373.0K
YoY Change -42.07% 505.0%
Acquisitions
YoY Change
Other Investing Activities -$45.90M -$7.990M -$13.24M
YoY Change 474.49%
Cash From Investing Activities -$46.60M -$9.200M -$13.61M
YoY Change 406.55% 4500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $34.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.41M 41.59M 34.00K
YoY Change -67.76% 58.56%
NET CHANGE
Cash From Operating Activities -3.985M -21.90M -9.638M
Cash From Investing Activities -46.60M -9.200M -13.61M
Cash From Financing Activities 13.41M 41.59M 34.00K
Net Change In Cash -37.18M 10.49M -23.21M
YoY Change -454.43% -26.28%
FREE CASH FLOW
Cash From Operating Activities -$3.985M -$21.90M -$9.638M
Capital Expenditures -$701.0K -$1.210M $373.0K
Free Cash Flow -$3.284M -$20.69M -$10.01M
YoY Change -84.13% 78.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20843367
CY2021Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
15232275
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15232275
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3452000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
198000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37191005
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108399000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37191005
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-104947000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2130139
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46542000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2130139
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
452357000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156438000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
295896000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
347074000
CY2020Q2 us-gaap Revenues
Revenues
67000
us-gaap Revenues
Revenues
231000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9166000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33834000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15953000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2011000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8353000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4133000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
11177000
us-gaap Operating Expenses
OperatingExpenses
42187000
us-gaap Operating Expenses
OperatingExpenses
20086000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11110000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42187000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19855000
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
51000
us-gaap Investment Income Net
InvestmentIncomeNet
232000
us-gaap Investment Income Net
InvestmentIncomeNet
163000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
163000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8535000
CY2020Q4 bolt Convertible Preferred Stock Purchase Right Liability Non Current
ConvertiblePreferredStockPurchaseRightLiabilityNonCurrent
25224000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
329000
CY2020Q4 us-gaap Liabilities
Liabilities
46193000
CY2021Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19691000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.45
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2083197
bolt Vesting Of Early Exercised Options And Restricted Stock Awards
VestingOfEarlyExercisedOptionsAndRestrictedStockAwards
9000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
448000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Net Income Loss
NetIncomeLoss
-19692000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-65041000
us-gaap Profit Loss
ProfitLoss
-48039000
us-gaap Profit Loss
ProfitLoss
-19692000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
211000
us-gaap Share Based Compensation
ShareBasedCompensation
4132000
us-gaap Share Based Compensation
ShareBasedCompensation
448000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1034000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
53000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
23000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1000
bolt Change In Fair Value Of Convertible Preferred Stock Purchase Rights Liabilities
ChangeInFairValueOfConvertiblePreferredStockPurchaseRightsLiabilities
6084000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
382000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-438000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2821000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-69000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
7000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21903000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1213000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
13235000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5247000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9201000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
41546000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
39000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59867000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45891000
CY2021Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105296000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19707000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4054000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
23761000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23761000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
176000
bolt Change In Fair Value Of Convertible Preferred Stock Purchase Rights Liabilities
ChangeInFairValueOfConvertiblePreferredStockPurchaseRightsLiabilities
6084000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
176000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5852000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23585000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11059000
us-gaap Net Income Loss
NetIncomeLoss
-48039000
us-gaap Net Income Loss
NetIncomeLoss
-19692000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23544000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11048000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48062000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36595112
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2089320
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29088267
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
303248000
CY2021Q2 bolt Issuance Of Common Stock Related To Stock Purchase Agreement
IssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000
CY2021Q2 bolt Vesting Of Early Exercised Options And Restricted Stock Awards
VestingOfEarlyExercisedOptionsAndRestrictedStockAwards
88000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2023000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23585000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
295896000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-54225000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2020Q2 bolt Vesting Of Early Exercised Options And Restricted Stock Awards
VestingOfEarlyExercisedOptionsAndRestrictedStockAwards
4000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
223000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11059000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-65041000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-104947000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
188506000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
241959000
bolt Issuance Of Common Stock Related To Stock Purchase Agreement
IssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
152000
bolt Vesting Of Early Exercised Options And Restricted Stock Awards
VestingOfEarlyExercisedOptionsAndRestrictedStockAwards
98000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4132000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Net Income Loss
NetIncomeLoss
-48039000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
295896000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-45846000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
528000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1174000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
885000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
632000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4110000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-278000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
11363000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20545000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
761000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
247768000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11406000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-237123000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
51902000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
244316000
bolt Proceeds From Issuance Of Common Stock Related To Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
572000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
310428000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41585000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52760000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10481000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7107000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35410000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58302000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45307000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
584000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59867000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45891000
bolt Vesting Of Exercised Options
VestingOfExercisedOptions
98000
bolt Vesting Of Exercised Options
VestingOfExercisedOptions
9000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
226000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
280000
bolt Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
216000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14884000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
324000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
252646000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
19000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the valuation of common stock, stock-based compensation, convertible preferred stock purchase right liabilities and accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. </p>
CY2021Q1 bolt Deferred Offering Costs To Offset Against Proceeds From Ipo
DeferredOfferingCostsToOffsetAgainstProceedsFromIPO
4000000.0
CY2020Q4 bolt Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
2400000
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. At June 30, 2021 and December 31, 2020, most of the Company’s funds are invested with a registered investment manager and custodied at one financial institution, with working capital kept at a separate financial institution, and account balances may at times exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions where the funds are held. </p>
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1600000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1600000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
41000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
252624000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
17296000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
17296000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6309000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5322000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1758000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1239000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4551000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4083000
CY2021Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
CY2020Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
200000
CY2021Q2 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
7054000
CY2020Q4 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3199000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2414000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2885000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1515000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
579000
CY2021Q2 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10983000
CY2020Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6663000
CY2021Q2 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.108
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
902000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
603000
us-gaap Operating Lease Cost
OperatingLeaseCost
1669000
us-gaap Operating Lease Cost
OperatingLeaseCost
1196000
us-gaap Operating Lease Payments
OperatingLeasePayments
666000
us-gaap Operating Lease Payments
OperatingLeasePayments
3133000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2446000
CY2021Q2 bolt Lessee Operating Sublease Income Receivable Remainder Of Fiscal Year
LesseeOperatingSubleaseIncomeReceivableRemainderOfFiscalYear
646000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4994000
CY2021Q2 bolt Lessee Operating Sublease Income Due Next Twelve Months
LesseeOperatingSubleaseIncomeDueNextTwelveMonths
1048000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4612000
CY2021Q2 bolt Lessee Operating Sublease Income Due Year Two
LesseeOperatingSubleaseIncomeDueYearTwo
403000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4772000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4227000
CY2021Q2 bolt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
19709000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
40760000
CY2021Q2 bolt Lessee Operating Sublease Income
LesseeOperatingSubleaseIncome
2097000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15277000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
25483000
us-gaap Sublease Income
SubleaseIncome
2097000
CY2018Q3 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
249218
CY2018Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-07-26
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.07
us-gaap Net Income Loss
NetIncomeLoss
-48039000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2023000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
223000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4132000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
448000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23585000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11059000
us-gaap Net Income Loss
NetIncomeLoss
-19692000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36617390
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1937510
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29104021
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1935575
CY2021Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
22279
CY2020Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
20213
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
33553
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
24401
CY2020Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
172023
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
17798
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
172023
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36595112
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2089320
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29088267
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2083197
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.45
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5102618
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17241208

Files In Submission

Name View Source Status
0001564590-21-044002-index-headers.html Edgar Link pending
0001564590-21-044002-index.html Edgar Link pending
0001564590-21-044002.txt Edgar Link pending
0001564590-21-044002-xbrl.zip Edgar Link pending
bolt-10q_20210630.htm Edgar Link pending
bolt-10q_20210630_htm.xml Edgar Link completed
bolt-20210630.xsd Edgar Link pending
bolt-20210630_cal.xml Edgar Link unprocessable
bolt-20210630_def.xml Edgar Link unprocessable
bolt-20210630_lab.xml Edgar Link unprocessable
bolt-20210630_pre.xml Edgar Link unprocessable
bolt-ex311_6.htm Edgar Link pending
bolt-ex312_8.htm Edgar Link pending
bolt-ex321_9.htm Edgar Link pending
bolt-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending